Lucrin Depot

Prostate Cancer
: 3 Month 11.25 mg is indicated in the palliative treatment of advanced prostatic cancer. It offers an alternative treatment of prostatic cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient.
Endometriosis
:
... Read more
Prostate Cancer
: 3 Month 11.25 mg is indicated in the palliative treatment of advanced prostatic cancer. It offers an alternative treatment of prostatic cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient.
Endometriosis
: 3 month 11.25 mg is indicated in the treatment of endometriosis for a period of six months. It can be used as sole therapy or as an adjunct to surgery.
Uterine Fibroids
: 3 month 11.25 mg is also indicated in the treatment of leiomyoma uteri (uterine fibroids) for a period up to six months. Therapy may be preoperative prior to myomectomy or hysterectomy, or it may provide symptomatic relief for the perimenopausal woman who does not desire surgery.
Breast Cancer
: 3 month 11.25 mg is also indicated for the treatment of breast cancer in pre- and peri-menopausal women in whom hormone therapy is specified.

Dosage & Administration

General
3 Month 11.25 mg must be administered under the supervision of a physician.
Upon reconstitution, the suspension should be discarded if not used immediately. the suspension should be discarded if not used immediately. As with other drugs administered by injection, the injection sites should be varied periodically.
Reconstitute the microspheres immediately prior to administration: 3 Month 11.25 mg mg, administered as a single subcutaneous or intramuscular injection every three months.
Use in treatment of endometriosis:
It is recommended that the therapy begin with the first day of the menstrual cycle after pregnancy has been ruled out. Development of amenorrhea is usually evidence of a clinical response, although spotting or bleeding from the atrophic endometrium can still occur.
Use in treatment of uterine fibroids
: Recommended duration of therapy is up to 6 months.

The following adverse events are commonly associated with the pharmacological actions of Lucrin Depot on the steroidogenesis
Men:
Neoplasm benign, malignant and unspecified (including cysts and polyps)
: prostate tumor flare, aggravation of prostate cancer
Metabolism and nutrition disorders
: weight gain, weight loss Psychiatric disorders: Loss or decreased libido, increase libido Nervous system disorders: headache, muscular weakness
Vascular disorders
: vasodilatation, hot flushes, hypotension, orthostatic hypotension
Skin and subcutaneous tissue disorders
: dry skin, hyperhydrosis, rash, urticaria, hair growth abnormal, hair disorder, night sweats, hypotrichosis, pigmentation disorder, cold sweat, hirsutism
Reproductive system and breast disorders
: gynaecomastia, breast tenderness, erectile dysfunction, testicular pain, breast enlargement, breast pain, prostate pain, penile swelling, penis disorder, testis atrophy
General disorders and administration site conditions
: mucosal dryness
Investigations
: PSA increased, bone density decreased
Long exposure (6 to 12 months)
: Diabetes mellitus, glucose tolerance impaired, total cholesterol increased, LDL increased, triglycerides increased, osteoporosis.
Women:
Metabolism and nutrition disorders
: weight gain, weight loss
Psychiatric disorders
: Loss or decreased libido, increased libido, affects lability
Nervous system disorders
: headache
Vascular disorders
: hot flushes, vasodilatation, hypotension
Skin and subcutaneous tissue disorders
: acne, seborrhea, dry skin, urticaria, skin odour abnormal, hyperhydrosis, hair growth abnormal, hirsutism, hair disorder, eczema, nail disorder, night sweats
Reproductive system and breast disorders
: vaginal haemorrhage, dysmenorrhea, menstrual disorder, breast enlargement, breast engorgement, breast atrophy, genital discharge, vaginal discharge, galactorrhea, breast pain, metrorrhagia, menopausal symptoms, dyspareunia, uterine disorder, vaginitis, menorrhagia
General disorders and administration site conditions
: feeling hot, irritability
Investigations
: bone density decreased
Long exposure (6 to 12 months)
: Diabetes mellitus, glucose tolerance impaired, total cholesterol increased, LDL increased, triglycerides increased, osteoporosis.

All Populations
: As the effect of Lucrin Depot for Depot Suspension – 3 Month 11.25 mg is present throughout the course of therapy, the drug should only be used in patients who require hormonal suspension for at least three months.
During the early phase of therapy, gonadotropins and sex steroids rise above baseline because
of the natural stimulatory effect of the drug. Therefore, an increase in clinical signs and symptoms may be observed
Worsening of pre-existing signs and symptoms during the first weeks of treatment may occur. Worsening of symptoms may contribute to paralysis with or without fatal complications.
Bone Mineral Density
: Bone mineral density changes can occur during any hypoestrogenic state in women and in long-term use in prostate cancer in men. There is no data in men regarding reversibility after withdrawal of Lucrin Depot. In women, bone mineral density loss may be reversible after withdrawal of Lucrin Depot.
Convulsions
: Postmarketing reports of convulsions have been observed in patients on Lucrin Depot therapy. These included patients in the female and pediatric populations, patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs. Convulsions have also been reported in patients in the absence of any of the conditions mentioned above.

Leuprorelin acetate, a GnRH agonist, acts as a potent inhibitor of gonadotropin secretion when given on a continuous basis and in therapeutic doses. Animal and human studies indicate that following an initial stimulation, chronic administration of leuprorelin acetate results in suppression Administration of leuprorelin acetate has resulted in inhibition of the growth of certain hormone dependent tumors (prostatic tumors in Nobel and Dunning male rats and DMBA-induced mammary tumors in female rats), as well as atrophy of the reproductive organs.
In humans, administration of leuprorelin acetate results in an initial increase in circulating levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH), leading to a transient increase in levels of the gonadal steroids (testosterone and dihydrotestosterone in males, and estrone and estradiol in pre-menopausal females).
However, continuous administration of leuprorelin acetate results in decreased levels of LH and FSH and sex steroids. In males, testosterone is reduced to castrate or prepubertal levels. In pre-menopausal females, estrogens are reduced to post-menopausal levels. These hormonal changes occur within a month of initiating drug therapy at recommended doses.